To test the hypothesis that heterogeneity of infiltrating CD8+ T cell fate may, at least in part, explain this paradox, we performed deep epigenetic profiling at the single-cell level, along with scRNA/TCR-seq and flow cytometry of immune cells from treatment-naive ccRCC patients. This evidence concerns the gene CD8A and nonpapillary renal cell carcinoma.